+51.7%
B vs MRNA
+485.7%
-434.0%
-33.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | +5.4% | -4.9% | +0.2% |
| 7D | -2.4% | -1.1% | -1.3% | -2.3% |
| 30D | +6.3% | +126.1% | -119.8% | -3.8% |
| 3M | +12.1% | +190.0% | -177.9% | -5.2% |
| 6M | -3.1% | +157.2% | -160.3% | -16.5% |
| YTD | +2.0% | +388.2% | -386.2% | -23.6% |
| 1Y | +51.7% | +467.0% | -415.4% | +8.2% |
| All | +51.7% | +485.7% | -434.0% | +8.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling